Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maria Dolores Garmendia
Institution:
Hospital Universitario Fundación Jiménez Díaz
Observed institution:
Hospital Universitario Fundación Jiménez Díaz
ORCID:
0009-0005-9701-6053
Observed ORCID:
0009-0005-9701-6053
OpenAlex ID:
A5128904129
Supplementary Table S3 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Data from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
7
Citation count:
H-index:
I10-index:
Year
Topic
Type